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Background. Protective factors against Gleason upgrading and its impact on outcomes after surgery warrant better definition.
Patients and Methods. Consecutive 343 patients were categorized at biopsy (BGS) and prostatectomy (PGS) as Gleason score, ≤6, 7,
and ≥8; 94 patients (27.4%) had PSA recurrence, mean followup 80.2 months (median 99). Independent predictors of Gleason
upgrading (logistic regression) and disease-free survival (DFS) (Kaplan-Meier, log-rank) were determined. Results. Gleason
discordance was 45.7% (37.32% upgrading and 8.45% downgrading). Upgrading risk decreased by 2.4% for each 1 g of prostate
weight increment, while it increased by 10.2% for every 1 ng/mL of PSA, 72.0% for every 0.1 unity of PSA density and was 21 times
higher for those with BGS 7. Gleason upgrading showed increased clinical stage (𝑃 = 0.019), higher tumor extent (𝑃 = 0.009),
extraprostatic extension (𝑃 = 0.04), positive surgical margins (𝑃 < 0.001), seminal vesicle invasion (𝑃 = 0.003), less “insignificant”
tumors (𝑃 < 0.001), and also worse DFS, 𝜒2 = 4.28, df = 1, 𝑃 = 0.039. However, when setting the final Gleason score (BGS ≤ 6 to
PGS 7 versus BGS 7 to PGS 7), avoiding allocation bias, DFS impact is not confirmed, 𝜒2 = 0.40, df = 1, 𝑃 = 0.530. Conclusions.
Gleason upgrading is substantial and confers worse outcomes. Prostate weight is inversely related to upgrading and its protective
effect warrants further evaluation.
1. Introduction
Gleason score (GS) remains themostwidely accepted grading
system in the evaluation of prostate cancer and is one of
the most important factors influencing tumor prognosis
and treatment choice for patients diagnosed with prostate
cancer [1]. Nevertheless, several studies have reported a
poor Gleason score concordance between biopsy and radical
prostatectomy (RP) specimens [1–4].
Failure of accurately obtaining the biopsy specimen to
precisely reflect the true nature of the cancer is especially
important for patients considering nonextirpative treat-
ments, such as external beam radiotherapy, brachytherapy,
cryotherapy, or expectant management [5].
Also, whether the clinical outcome of Gleason score dis-
cordance is similar to that of concordant tumors of the higher
grade, concordant tumors of the lower grade, or somewhere
in between remains to be solved.
Targeting a better guidance to patients during their
treatment decision process, we investigated factors predictive
of Gleason score upgrading between biopsy and surgical
specimens and the impact of discordance scores on postop-
erative outcomes.
2. Materials and Methods
2.1. Patient Selection. A prospectivelymaintained database of
360 consecutive patients who underwent 10–12 core prostate
biopsy and radical prostatectomy at our institution from
1997 to 2009 was reviewed after institutional review board
approval.
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Patients who received prior hormone treatment or radio-
therapy or refused to authorize the use of their medical
records were excluded.
2.2. Pathologic Evaluation. Gleason scores of biopsy and
prostatectomy were reanalyzed and regraded by pathological
review and categorized as ≤6, 7, and ≥8 by an expert uropa-
thologist (Athanase Billis) according to the 2005 Interna-
tional Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma [7].
Upgrading was considered RP grade in a higher category
than the biopsy and downgrading the opposite. After tran-
secting the seminal vesicles at the base, the prostate glandwas
weighed when fresh after RP, using an electronic scale and its
weight was recorded in grams.
The tumor extent was evaluated by a semiquantitative
point-count method [6]. Briefly, each quadrant of the whole
mount sections of the surgical specimen, which contained
eight equidistant points, was drawn on a sheet of paper.
During the microscopic examination of the slides, the tumor
area was drawn on the correspondent quadrant seen on the
paper. The amount of positive points represented an estimate
of the tumor extent. More extensive tumors corresponded
to >26 positive points and “insignificant” tumors, defined
as having volume <0.5 cc and no Gleason grade 4 or 5
component (primary, secondary or tertiary) corresponded
approximately to ≤10 positive points [6].
2.3. Follow-Up Regimen. Evaluated parameters included age,
prostate weight, preoperative prostate-specific antigen (PSA)
level, PSA density, and tumor extent as continuous vari-
ables, and race, biochemical recurrence (BCR), clinical and
pathological stages, Gleason grade, extraprostatic extension,
positive surgical margins, seminal vesicle invasion, and
“insignificant” tumors as categorical variables.
During the postoperative period, serum PSA was drawn
every 3 months during the first year, every 6 months during
the second year, and annually thereafter. Total serumPSAwas
measured using previous validated Immulite PSA kit. PSA
≥0.2 ng/mL after surgery was considered BCR, according
to recommendation of the American Urological Association
[8]. Patients without evidence of BCR were censored at last
followup for disease-free survival (DFS) analyses.
2.4. Statistical Analysis. The chi-square or Fisher’s exact test
(for expected values less than 5) was used to compare the
major categorical variables, the Mann-Whitney test to com-
pare numerical variables between two groups, and Kruskal-
Wallis test for comparing numerical variables between three
or more groups.TheMcNemar’s test (two categories) and the
Bowker’s test of symmetry (three categories) were applied to
compare the biopsy Gleason score (BGS) and pathological
Gleason score (PGS).
The uni- and multivariate stepwise logistic regression
analyses were utilized to study PGS score upgrading pre-
dictors. The analysis of Receiver Operating Characteristic
(ROC), the area under the curve (AUC), 95% confidence
interval, and the levels of sensitivity and specificity were
calculated for accurate cut-offs discriminations.
Postoperative disease-free survival was estimated using
the Kaplan-Meier method and compared with the log-rank
test. A two-sided 5% significance level was adopted for
statistical tests (𝑃 < 0.05).
3. Results
After exclusion criteria, 343 patients met our standards for
analysis and the discordance between BGS and PGS was
45.7%. Table 1 lists patient’s demographics in each one of the
groups: BGS = PGS (54.23%, 𝑛 = 186), BGS < PGS (37.32%,
𝑛 = 128), and BGS > PGS (8.45%, 𝑛 = 29).
The mean age of the population was 63.46 (SD = 6.56)
years (median 64), and the average weight of all prostates was
40.56 g (median 35; range 11–190). During the mean followup
of 80.2 months (median 99), 94 patients (27.4%) had PSA
recurrence after radical prostatectomy. Mean pretreatment
PSA was 9.63 (SD = 6.72, median = 7.92), range 0.28–51.
Gleason upgrading led patients to increased clinical stage
(𝑃 = 0.019), more positive points in surgical specimen (𝑃 =
0.009), extraprostatic extension (𝑃 = 0.04), positive surgical
margins (𝑃 < 0.001), seminal vesicle invasion (𝑃 = 0.003),
and less “insignificant” tumors (𝑃 < 0.001).
Tables 2 and 3 present the results of the uni- and
multivariate logistic regression analyses to predict Gleason
discordance between biopsy and RP.
According to multivariate logistic regression analysis,
lower prostate weight (𝑃 < 0.001), higher PSA (𝑃 = 0.003),
higher PSA density (𝑃 < 0.001), and higher BGS (𝑃 < 0.001)
were significantly associated with PGS upgrading. While the
upgrading risk decreased 2.4% for each 1 g of prostate weight,
it increased 10.2% for every 1 ng/mL of PSA, 72.0% for every
0.1 unity of PSA density, and was 21 times higher for those
with BGS 7 (Table 3).
Patients with Gleason upgrade presented worse disease-
free survival compared with concordant Gleason tumors,
log-rank test: 𝜒2 = 4.28, df = 1, and 𝑃 = 0.039
(Figure 1).
Focusing on PGS 7, comparing PGS 7 that have upgraded
(BGS ≤ 6 to PGS 7) with those that was accurately diagnosed
on biopsy (BGS 7 to PGS 7), the last were significantly
associated with extraprostatic tumor extension (𝑃 = 0.039),
>pT2 pathological stage (𝑃 = 0.023), and older age (𝑃 <
0.001). However, disease-free survival was not different, log-
rank test: 𝜒2 = 0.40, df = 1, and 𝑃 = 0.530, when
comparing BGS ≤ 6 to PGS 7 versus BGS 7 to PGS 7,
(Figure 2).
When associating PSA and prostate volume to pre-
dict Gleason score upgrading on radical prostatectomy
specimens, PSA density ≥ 0.263 significantly discriminated
between patients with and without upgrading at surgery
(𝑃 < 0.001), AUC: 0.696, CI 95% 0.638–0.753, sensitivity:
48.8%/specificity: 85.2%, (Figure 3), and also determined
disease-free survival, log-rank: 𝜒2 = 22.76; GL = 1;
𝑃 < 0.001, (see Supplementary Figure available online at
http://dx.doi.org/10.1155/2013/710421).
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Table 1: Patients’ demographics by Gleason score at biopsy versus radical prostatectomy (RP).
Feature Gleason score 𝑃 value
Biopsy < RP (upgraded) Biopsy = RP Biopsy > RP (downgraded)
Overall 128 (37.32%) 186 (54.23%) 29 (8.45%)
Age (Median/Min Max) 62.76 (43–76) 63.94 (46–76) 63.55 (46–74) 0.317
Race 0.522
White 98 (76.56%) 156 (83.87%) 24 (82.76%)
Black 28 (21.88%) 27 (14.52%) 5 (17.24%)
Yellow 2 (1.56%) 3 (1.61%) 0
PSA 10.29 (0.28–8.60) 8.95 (0.6–29.7) 11.1 (3.10–44) 0.192
Prostate weight 37.45 (15–94) 42.34 (11–190) 42.30 (15–110) 0.373
PSA density 0.31 (0.06–0.86) 0.25 (0.09–0.66) 0.19 (0.03–0.63) <0.001
Clinical stage 0.019
T1c 52 (44.44%) 99 (56.25%) 8 (30.77%)
T2a 46 (39.32%) 58 (32.95%) 10 (38.46%)
T2b 13 (11.11%) 17 (9.66%) 7 (26.02%)
T2c 6 (5.13%) 2 (1.14%) 1 (3.85%)
Biopsy Gleason score <0.001
≤6 115 (89.84%) 99 (53.23%) 0
7 13 (10.16%) 84 (45.16%) 19 (65.52%)
≥8 0 3 (1.61%) 10 (34.48%)
Pathological Gleason score <0.001
≤6 0 100 (53.76%) 18 (62.07%)
7 112 (87.50%) 83 (44.62%) 11 (37.93%)
≥8 16 (12.50%) 3 (1.61%) 0
Pathological stage 0.05
≤pT2 81 (63.28%) 139 (74.73%) 23 (79.31%)
47 (36.72%) 47 (25.27%) 6 (20.69%)
Positive points (tumor extent)
≤26 44 (37.93%) 98 (55.06%) 15 (60.00%) 0.009
72 (62.07%) 80 (44.94%) 10 (40.00%)
Positive points (median/min max) 46.70 (1.00–33.50) 29.76 (0–222) 33.32 (1.0–152) <0.001
“Insignificant” tumors∗ <0.001
Yes 0 (0.00%) 22 (12.43%) 3 (12.50%)
No 116 (100.00%) 155 (87.57%) 21 (87.50%)
Positive surgical margin <0.001
No 51 (40.16%) 114 (61.29%) 20 (68.97%)
Yes 76 (59.84%) 72 (38.71%) 9 (31.03%)
Extra prostatic extension 0.043
No 81 (63.78%) 141 (75.81%) 23 (79.31%)
Yes 46 (36.22%) 45 (24.19%) 6 (20.69%)
Seminal vesicle invasion 0.003
No 103 (82.40%) 174 (94.57%) 25 (86.21%)
Yes 22 (17.60%) 10 (5.43%) 4 (13.79%)
∗Based on classification of Billis et al. [6].
4. Discussion
Gleason score discordance between biopsy and radical
prostatectomy specimens is a common finding, with 32%–
73% rates reported in the literature [2–4, 9], being more con-
cordant in departments of pathology that regularly evaluate
RP specimens (>40RP specimens annually) [5].
Upgrading is the most common problem and downgrad-
ing is found in only about 10–15% of cases. In general, adverse
findings on needle biopsy accurately predict adverse findings
in RP specimen, whereas favorable findings in needle biopsy
do not necessarily predict favorable findings in RP specimens
in large part due to sampling error, borderline cases, pathol-
ogy error, intraobserver and interobserver variability [10].
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Table 2: Univariate logistic regression analysis to preoperatively predict Gleason discordance.
Variable Categories 𝑃 value Odds ratio CI 95% OR
Race White
∗ — 1.00 —
Black 0.281 1.38 0.77–2.49
Age Years 0.049 1.035 1.001–1.070
Clinical stage
T1c∗ — 1.00 —
T2a 0.030 1.79 1.06–3.03
T2b 0.438 0.75 0.37–1.55
T2c 0.128 5.11 0.62–41.81
Clinical stage (T1c × T2) T1c
∗ — 1.00 —
T2 0.092 1.49 0.94–2.37
PSA ng/dL <0.001 1.080 1.032–1.130
PSA (> or <10 ng/ml) <10 ng/mL
∗ — 1.00 —
>10 ng/mL <0.001 2.48 1.50–4.11
Prostate weight g 0.005 0.984 0.973–0.995
PSA density 0.1 unity <0.001 1.713 1.394–2.104
Biopsy Gleason score ≤6
∗ — 1.00 —
7 <0.001 19.13 7.50–48.80
∗Categories of reference; CI: confidence interval; OR: odds ratio.
Table 3: Significant variables on multivariate logistic regression analysis to preoperatively predict Gleason discordance.
Variables Categories 𝑃 value Odds ratio CI 95% OR
Biopsy Gleason score ≤6
∗ — 1.00 —
7 <0.001 21.04 7.77–56.99
Prostate weight g <0.001 0.976 0.962–0.990
PSA ng/dL 0.003 1.102 1.033–1.175
PSA density 0.1 unity <0.001 1.720 1.400–2.113
∗Category of reference; OR: odds ratio.
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Figure 1:Disease-free survival byGleason score between biopsy and
radical prostatectomy (1: concordant; 2: upgrade).
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Figure 2: Disease-free survival by Gleason score between biopsy
and radical prostatectomy (“2–6” to “7” versus “7” to “7”).
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Figure 3: Receiver Operating Characteristic curve analysis for PSA
density to preoperatively predict Gleason discordance.
Although prior radical prostatectomy series have shown
that patients with a lower BGS experienced significantly
better DFS than patients with equal BGS and PGS, suggesting
that BGS represents additional prognostic value to PGS [11,
12], in our data while patients with equal BGS and PGS have
presented a significant increment of extraprostatic tumor
extension (𝑃 = 0.039), >pT2 pathological stage (𝑃 = 0.023)
and older age (𝑃 < 0.001) DFS was not different when
comparing BGS ≤ 6 to PGS 7 versus BGS 7 to PGS 7.
Our study is consistent with contemporary data, par-
ticularly in the era of PSA and routine 12 core biopsies
[13–17], associating Gleason score discordance with adverse
pathological features (advanced tumor stage, more positive
points in surgical specimen, extraprostatic extension, positive
surgical margins, seminal vesicle invasion, and lower rates
of “insignificant” tumors) and worse DFS. However, the
real independent impact of Gleason upgrading on DFS may
be questioned, since when setting the final Gleason score
(BGS ≤ 6 to PGS 7 versus BGS 7 to PGS 7), avoiding
allocation bias, DFS effect is not confirmed, 𝜒2 = 0.40, df
= 1, 𝑃 = 0.530, supporting a failure of the initial biopsy
to accurately reflect the prostatectomy Gleason score or to
add enough prognostic influence that may be applicable to
strategies of risk stratification and patient counseling after
surgery.
Together these data support the concept that RP patho-
logical parameters provide an improved prognostic assess-
ment of outcome in men with clinically localized prostate
cancer than biopsy parameters [15, 16].
Intriguingly, the multivariate logistic regression analysis
showed that prostate weight was a protective factor, decreas-
ing 2.4% upgrading risk for each 1 g of prostate weight, while
higher BGS, PSA levels, and PSA density were selected as
being significantly associated with further PGS upgrading.
The protective effect of (higher) prostate weight is an
underexplored paradox phenomenon since it is expected that
the larger the prostate, the greater the sampling error.
Keeping the number of cores around 10 to 12, according to
the current optimal technique, the biopsy artifact hypothesis
seems to be an insufficient explanation. If sampling error
was the central cause of Gleason upgrading, then upgraded
tumors would represent larger prostates, smaller tumor bur-
den, or both comparedwith tumors concordant for the higher
grade, strikingly conflicting with our results.
Among many assumptions, larger glands may produce
more PSAdue to the presence of benign prostatic hyperplasia,
causing a lead-time bias or diagnosis of prostate cancer at an
earlier point in the progression of disease, which could justify
the protective effect of larger glands regarding upgrading.
Otherwise, a large prostate might work as an obstacle to the
growth of cancer cells, culminating with less extracapsular
extension and consequently less positive surgicalmargins and
lower biochemical recurrence.
Regardless of the mechanism, it offers the opportunity
to accurately predict the final pathological grade based on
clinical parameters, improving our ability to inform patients
and guide their care. However, it is startling that many pre-
diction tools, such as nomograms, have not taken advantage
of the size-weight/grade relationship, neither for surgery nor
radiotherapy [18].
Though there is an association between smaller prostates
and Gleason upgrading on uni- and multivariate analysis,
aiming to better understand the influence of prostate size,
PSA, and Gleason upgrade connection, this study measured
the association between PSA and prostate volume once
smaller size prostate tends to have a higher PSA density and
be more likely to harbor high-grade disease as demonstrated
in this study and elsewhere [19, 20].
PSA density adds the mixed impact of both PSA and
prostate volume, being also a strong independent predictor
of Gleason upgrade. Thus, PSA being an important diag-
nostic tool, it selects patients for prostate biopsy, inputting
PSA related allocation bias. In this scenario, observing that
smaller prostates are more likely to have upgraded cancer is
somewhat related to the performance characteristics of PSA.
We interpret this to mean that when controlling prostate size,
PSA is the additional important driver behind upgrading;
however, beware of the small prostate once the influence of
PSA is subtle.
The limits of this study are those of any retrospective
analysis, the relatively small number of patients, and the
lack of overall and disease specific survival, limiting to DFS;
however, all prostatectomies was performed at a single insti-
tution and a single expert uropathologist reviewed all biopsies
and whole-mount RP slides, also detailed morphometric
mapping were used to estimate tumor extent and to evaluate
margin status, extracapsular extension, or foci of high-
grade cancer. Furthermore, this series particularly focuses on
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the Gleason upgrade issue in real contemporary scenery
of PSA and routine 10–12 core biopsies era, utilizing the
modified 2005 Gleason system.
While the use of final pathological prostate weight should
be viewed as a limitation, it has been shown to correlate well
with trans-rectal ultrasound prostate volume [21, 22], and
both are final pathological Gleason score predictors.
Lastly, we analyzed prostate weigh, PSA and PSA density
as continuous variables, giving complete information in
addition to categorical variables in others studies. Also,
Gleason score up- and downgrading was considered among
more representative classes: ≤6, 7, and ≥7; once between 2 to
6 (lower risk range) and 8 to 10 (higher risk range) there is a
recognized less powerful risk stratification.
5. Conclusions
Gleason score discordance between biopsy and radical
prostatectomy specimens in prostate cancer patients is sub-
stantial and has potential clinical significance in predicting
worse oncologic outcomes.
Prostate weight is inversely associated with Gleason
upgrading in RP specimens and its protective effect warrants
further evaluation, focusing on using prostate size in models
to predict upgrading and downgrading on final pathology
and outcomes.
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